Human Insulin Market to reach USD 24.6 billion by 2032 and grow at a CAGR of 3.4%.
Revolutionary growth in the market is experienced in human insulin, mainly due to the increase in the prevalence of diabetes and regulatory developments that make the treatment more accessible. According to IDF data, as many as 537 million people in the world are suffering from the disease, and by 2045, this number will increase to 643 million. This increase in diabetic patients, driven by sedentary lifestyles, is fueling the rising demand for insulin products that are vital in the treatment of diabetes. In developed countries, positive reimbursement scenarios also bolster the market.